Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRMD | CORMEDIX INC | $835.60M | $12.32 | $17.00 | 37.99% | Buy | 6 | 57.11% | 113.60% | 184.78% | 141.92% | |||
| CORT | CORCEPT THERAPEUTICS INC | $7.78B | $73.40 | $142.00 | 93.46% | Strong Buy | 4 | 31.13% | 52.86% | 126.10% | 101.79% | |||
| GYRE | GYRE THERAPEUTICS INC | $689.12M | $7.35 | N/A | N/A | N/A | N/A | 52.00% | 179.85% | 399.13% | 209.49% | |||
| ARGX | ARGENX SE | $33.49B | $551.22 | $755.80 | 37.11% | Strong Buy | 10 | 976.47% | 26.11% | 39.84% | 35.32% | |||
| TGTX | TG THERAPEUTICS INC | $5.71B | $35.99 | $55.00 | 52.82% | Buy | 1 | 37.60% | 104.81% | 225.80% | 81.59% | |||
| VCEL | VERICEL CORP | $2.14B | $42.55 | $61.25 | 43.95% | Strong Buy | 4 | 25.79% | 196.11% | 35.10% | 24.43% | |||
| RPRX | ROYALTY PHARMA PLC | $20.26B | $36.03 | N/A | N/A | N/A | N/A | 20.30% | 43.19% | 31.42% | 17.47% | |||
| KRYS | KRYSTAL BIOTECH INC | $3.97B | $137.46 | $210.50 | 53.14% | Strong Buy | 6 | 34.23% | 35.87% | 34.31% | 31.44% | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.14B | $8.47 | N/A | N/A | N/A | N/A | 17.88% | 64.08% | 76.77% | 53.25% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.81B | $31.60 | $55.17 | 74.58% | Strong Buy | 6 | 15.87% | 23.30% | 52.24% | 35.66% | |||
| ADMA | ADMA BIOLOGICS INC | $4.35B | $18.21 | $28.50 | 56.51% | Strong Buy | 2 | 19.85% | 13.30% | 108.68% | 79.49% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.65B | $21.70 | $32.50 | 49.77% | Strong Buy | 4 | 10.42% | 16.72% | 40.85% | 35.70% | |||
| MNKD | MANNKIND CORP | $1.14B | $3.74 | N/A | N/A | N/A | N/A | 13.97% | 40.10% | -212.58% | 30.38% | |||
| EXEL | EXELIXIS INC | $12.02B | $44.08 | $43.80 | -0.62% | Buy | 15 | 10.04% | 16.16% | 60.91% | 45.75% | |||
| HALO | HALOZYME THERAPEUTICS INC | $6.41B | $52.02 | $64.17 | 23.35% | Buy | 6 | 14.12% | 15.64% | 224.59% | 49.31% | |||
| INCY | INCYTE CORP | $13.18B | $68.10 | $75.00 | 10.13% | Hold | 10 | 8.66% | 196.38% | 45.13% | 28.79% | |||
| MDXG | MIMEDX GROUP INC | $902.46M | $6.11 | $13.00 | 112.77% | Strong Buy | 1 | 11.95% | 35.86% | N/A | N/A | |||
| TECH | BIO-TECHNE CORP | $8.07B | $51.45 | $72.00 | 39.94% | Buy | 10 | 7.69% | 56.97% | 15.89% | 12.12% | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $6.54B | $106.12 | $183.08 | 72.52% | Strong Buy | 12 | 5.80% | 48.52% | N/A | N/A | |||
| VCYT | VERACYTE INC | $2.12B | $27.03 | $42.00 | 55.38% | Strong Buy | 5 | 8.13% | 49.36% | 7.47% | 6.79% | |||
| NVO | NOVO NORDISK A S | $308.17B | $69.02 | $64.00 | -7.27% | Hold | 1 | 10.37% | 13.14% | 121.91% | 34.53% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.54B | $54.97 | $95.78 | 74.24% | Strong Buy | 9 | 9.05% | 23.96% | N/A | N/A | |||
| NAGE | NIAGEN BIOSCIENCE INC | $1.14B | $14.41 | $14.53 | 0.80% | Strong Buy | 4 | 18.38% | 8.02% | 40.56% | 27.60% | |||
| GMAB | GENMAB A | $13.68B | $20.66 | $36.33 | 75.86% | Strong Buy | 3 | 16.71% | 11.83% | 3.91% | 3.14% | |||
| ACAD | ACADIA PHARMACEUTICALS INC | $3.61B | $21.57 | $27.71 | 28.45% | Buy | 17 | 9.71% | 0.62% | 46.06% | 31.13% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.